Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
03
2020
accepted:
29
04
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
4
8
2020
Statut:
epublish
Résumé
CD4-positive T cells are the main target of human T-cell leukemia virus type 1 (HTLV-1). Interferon-γ release assays rely on the fact that T-lymphocytes release this cytokine when exposed to tuberculosis-specific antigens and are useful in testing for latent tuberculosis infection before initiating biologic therapy, such as anti-tumor necrosis factor agents. However, the reliability of interferon-γ release assays in detecting tuberculosis infection among HTLV-1-positive patients with rheumatoid arthritis (RA) remains unclear. The present study aimed to evaluate the use of the T-SPOT.TB assay in HTLV-1-positive RA patients. Overall, 29 HTLV-1-positive RA patients and 87 age- and sex-matched HTLV-1-negative RA patients (controls) were included from the HTLV-1 RA Miyazaki Cohort Study. Results of the T-SPOT.TB assay for latent tuberculosis infection screening were collected from medical records of patients. Approximately 55% of the HTLV-1-positive RA patients showed invalid T-SPOT.TB assay results (odds ratio: 108, 95% confidence interval: 13.1-890, p < 0.0001) owing to a spot count of >10 in the negative controls. HTLV-1 proviral load values were significantly higher in patients with invalid results compared with those without invalid results (p = 0.003). HTLV-1 infection affects T-SPOT.TB assay results in RA patients. Assay results in HTLV-1 endemic regions should be interpreted with caution when screening for latent tuberculosis infection before initiation of biologic therapy.
Sections du résumé
BACKGROUND
CD4-positive T cells are the main target of human T-cell leukemia virus type 1 (HTLV-1). Interferon-γ release assays rely on the fact that T-lymphocytes release this cytokine when exposed to tuberculosis-specific antigens and are useful in testing for latent tuberculosis infection before initiating biologic therapy, such as anti-tumor necrosis factor agents. However, the reliability of interferon-γ release assays in detecting tuberculosis infection among HTLV-1-positive patients with rheumatoid arthritis (RA) remains unclear. The present study aimed to evaluate the use of the T-SPOT.TB assay in HTLV-1-positive RA patients.
METHODS
Overall, 29 HTLV-1-positive RA patients and 87 age- and sex-matched HTLV-1-negative RA patients (controls) were included from the HTLV-1 RA Miyazaki Cohort Study. Results of the T-SPOT.TB assay for latent tuberculosis infection screening were collected from medical records of patients.
RESULTS
Approximately 55% of the HTLV-1-positive RA patients showed invalid T-SPOT.TB assay results (odds ratio: 108, 95% confidence interval: 13.1-890, p < 0.0001) owing to a spot count of >10 in the negative controls. HTLV-1 proviral load values were significantly higher in patients with invalid results compared with those without invalid results (p = 0.003).
CONCLUSION
HTLV-1 infection affects T-SPOT.TB assay results in RA patients. Assay results in HTLV-1 endemic regions should be interpreted with caution when screening for latent tuberculosis infection before initiation of biologic therapy.
Identifiants
pubmed: 32459801
doi: 10.1371/journal.pone.0233159
pii: PONE-D-20-06768
pmc: PMC7252607
doi:
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0233159Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Tuberculosis (Edinb). 2018 Jan;108:178-185
pubmed: 29523321
J Rheumatol Suppl. 2014 May;91:41-6
pubmed: 24788999
J Infect Dis. 2005 Apr 1;191(7):1140-7
pubmed: 15747250
Clin Infect Dis. 1993 Dec;17(6):968-75
pubmed: 8110954
PLoS One. 2009 Aug 05;4(8):e6517
pubmed: 19654865
Curr Opin Rheumatol. 2008 Jul;20(4):443-9
pubmed: 18525359
BMC Infect Dis. 2009 Dec 15;9:207
pubmed: 20003535
Ann Rheum Dis. 2005 Sep;64(9):1360-1
pubmed: 16100342
MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25
pubmed: 20577159
N Engl J Med. 2001 Oct 11;345(15):1098-104
pubmed: 11596589
J Med Virol. 2012 Feb;84(2):327-35
pubmed: 22170555
Mod Rheumatol. 2019 Sep;29(5):795-801
pubmed: 30246572
Viruses. 2018 Dec 05;10(12):
pubmed: 30563084
Lancet Infect Dis. 2004 Dec;4(12):761-76
pubmed: 15567126
J Med Virol. 2011 Jul;83(7):1269-74
pubmed: 21567429
J Med Virol. 2017 Aug;89(8):1469-1476
pubmed: 28252206
Int J Cancer. 1994 Feb 1;56(3):337-40
pubmed: 8314320
Int J Tuberc Lung Dis. 2016 Nov;20(11):1546-1553
pubmed: 27776599
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25
pubmed: 26545825
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Ann Rheum Dis. 2010 Mar;69(3):522-8
pubmed: 19854715
Arthritis Rheum. 2005 Jun;52(6):1766-72
pubmed: 15934089
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Int J Cancer. 1988 Dec 15;42(6):829-31
pubmed: 3192326
Arthritis Care Res (Hoboken). 2014 May;66(5):788-92
pubmed: 24127184
Arthritis Rheum. 1995 Jan;38(1):44-8
pubmed: 7818570
Ann Rheum Dis. 2008 Jan;67(1):84-90
pubmed: 17644549
Eur Respir J. 2010 Nov;36(5):1185-206
pubmed: 20530046
Blood. 2010 Aug 26;116(8):1211-9
pubmed: 20448111
Arthritis Rheumatol. 2018 Jul;70(7):1014-1021
pubmed: 29471588
Arthritis Rheum. 2009 Jul;60(7):1884-94
pubmed: 19565495